Objective:

To evaluate the awareness, clinical utilization, and perceived advantages and barriers to vonoprazan use for H. pylori infection and GERD among Chinese physicians, highlighting the significance of addressing knowledge gaps.

Key Findings:

• High prevalence of H. pylori infection (42.8%) and GERD (10.6%) in China, indicating a need for improved treatment strategies.
• Current treatment regimens for H. pylori are complex, leading to suboptimal adherence, which may result in increased morbidity.
• Vonoprazan shows promise as an alternative to PPIs with potential benefits in efficacy and patient adherence, suggesting a shift in treatment paradigms.

Interpretation:

The study highlights a significant gap in physician awareness and utilization of vonoprazan, which could negatively impact treatment outcomes for H. pylori and GERD in China, necessitating targeted educational interventions.

Limitations:

• Response rate could not be calculated due to broad distribution methods, which may introduce selection bias.
• Psychometric testing of the questionnaire was not performed, limiting the assessment of its reliability.

Conclusion:

Addressing the knowledge and perception gaps among physicians regarding vonoprazan may enhance its adoption and improve patient management for H. pylori and GERD, suggesting the need for targeted educational initiatives.